{
  "nctId": "NCT03379233",
  "briefTitle": "A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence",
  "officialTitle": "A 24-week Randomized, Controlled, Multicenter, Open-label Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence of COPD Subjects Receiving Ultibro® Breezhaler® Treatment Using the Concept2 Inhaler for Dose Administration and Tracking",
  "protocolDocument": {
    "nctId": "NCT03379233",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2018-05-18",
    "uploadDate": "2020-01-15T14:32",
    "size": 2388332,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03379233/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 7,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2018-07-11",
    "completionDate": "2019-01-22",
    "primaryCompletionDate": "2019-01-22",
    "firstSubmitDate": "2017-12-15",
    "firstPostDate": "2017-12-20"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Signed informed consent\n* Have a total adherence of more than 10% but less than or equal to 70% during Screening period\n* Current or ex-smokers who have a smoking history of at least 10 pack years.\n* A diagnosed COPD\n* Taking Ultibro® Breezhaler® for at least 3 month prior to Visit 1\n* Have been in the Screening period ≥ 35 days.\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Women of child-bearing potential\n* Subjects having a history of reactions/hypersensitivity to inhaled drugs or drugs of a similar class\n* Subjects having a history of reactions/hypersensitivity to lactose or any of the other ingredients of trial medication.\n* Subjects with relevant concomitant diseases\n* Subjects who have had a COPD exacerbation 6 weeks prior to Visit 1 or between V1 and randomization\n* Subjects who have had a respiratory tract infection within 3 weeks prior to Visit 1 or between V1 and randomization\n* Use of investigational drugs or other investigational devices at the time of enrollment\n* Subjects with a preferred inhalation time between 10.00 pm and 2.00 am.\n* Subjects taken off Ultibro® Breezhaler® treatment/inhaler use by the investigator during the Screening period for more than 7 days.\n* Subjects not returning all Concept2 inhalers received during the Screening period\n* Subjects who have demonstrated inability or unwillingness to use the digital system or to fill in questionnaires.\n\nOther protocol-defined inclusion/exclusion criteria may apply",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in Participant's On-time Adherence Over 24 Weeks of Intervention Compared to Baseline",
        "description": "On-time treatment adherence was defined as percentage of days on which the participant inhaled at least one dose on-time. Dose inhaled on-time was a dose inhaled within (+ or -) 2 hours of the agreed predefined preferred daily inhalation time (PIT). PIT was defined by the participant at study start.",
        "timeFrame": "Baseline 6 weeks, intervention 24 weeks"
      },
      {
        "measure": "Change in Participant's Total Adherence Over 24 Weeks of Intervention Compared to Baseline",
        "description": "Total adherence was defined as percentage of days on which the participant inhaled at least one dose and represented the sum of on-time adherence and off-time adherence. Off-time adherence was defined as percentage of days on which the participant did not inhale the daily dose within the (+ or -) 2 hours of the predefined PIT, but outside. The number of doses not inhaled on-time was recorded by the Concept2 inhaler.",
        "timeFrame": "Baseline 6 weeks, intervention 24 weeks"
      }
    ],
    "secondary": [
      {
        "measure": "Change From Participant's 6 Weeks Baseline On-time Adherence to the Participant's On-time Adherence Over the Last Four Weeks of Intervention",
        "description": "On-time treatment adherence was defined as percentage of days on which the participant inhaled at least one dose on-time. Dose inhaled on-time was a dose inhaled within (+ or -) 2 hours of the agreed predefined preferred daily inhalation time (PIT). PIT was defined by the participant at study start.",
        "timeFrame": "Baseline, Week 21 - 24"
      },
      {
        "measure": "Change From Participant's 6 Weeks Baseline Total Adherence to the Participant's Total Adherence Over the Last Four Weeks of Intervention",
        "description": "Total adherence was defined as percentage of days on which the participant inhaled at least one dose and represented the sum of on-time adherence and off-time adherence. Off-time adherence was defined as percentage of days on which the participant did not inhale the daily dose within the (+ or -) 2 hours of the predefined PIT, but outside. The number of doses not inhaled on-time was recorded by the Concept2 inhaler.",
        "timeFrame": "Baseline, Week 21 - 24"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 2,
      "otherCount": 0,
      "totalCount": 4
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 44,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:27.138Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}